miRNAs in acute myeloid leukemia

Qiong Liao; Bingping Wang; Xia Li; Guosheng Jiang

doi:10.18632/oncotarget.12343

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

miRNAs in acute myeloid leukemia

Qiong Liao, Bingping Wang, Xia Li _ and Guosheng Jiang

PDF | HTML | How to cite

Oncotarget. 2017; 8:3666-3682. https://doi.org/10.18632/oncotarget.12343

Metrics: PDF 3501 views | HTML 7111 views | ?

Abstract

Qiong Liao1,2,*, Bingping Wang3,*, Xia Li1,4 and Guosheng Jiang1

1 Key Laboratory for Rare & Uncommon Diseases of Shandong Province, Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan, Shandong, P.R. China

2 School of Medicine and Life Sciences, Jinan University, Jinan, Shandong, P.R. China

3 Department of Hematology, Shengli Oilfield Central Hospital, Dongying, Shandong, P.R. China

4 Shandong University School of Medicine, Jinan, Shandong, P.R. China

* These authors have contributed equally to this work

Correspondence to:

Xia Li, email:

Guosheng Jiang, email:

Keywords: miRNAs regulatory signaling pathways, acute myeloid leukemia, pathogenesis, prognosis, miRNA-directed therapy

Received: March 29, 2016 Accepted: September 24, 2016 Published: September 29, 2016

Abstract

MicroRNAs (miRNAs) are small, non-coding RNAs found throughout the eukaryotes that control the expression of a number of genes involved in commitment and differentiation of hematopoietic stem cells and tumorigenesis. Widespread dysregulation of miRNAs have been found in hematological malignancies, including human acute myeloid leukemia (AML). A comprehensive understanding of the role of miRNAs within the complex regulatory networks that are disrupted in malignant AML cells is a prerequisite for the development of therapeutic strategies employing miRNA modulators. Herein, we review the roles of emerging miRNAs and the miRNAs regulatory networks in AML pathogenesis, prognosis, and miRNA-directed therapies.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12343

Publication Alerts

Post-Publication Promotion

Reviews:

miRNAs in acute myeloid leukemia

Abstract